Takeda Unveils R&D, Commercial Realignments To Try For Post-Patent Gains
This article was originally published in PharmAsia News
TOKYO - Takeda Pharmaceutical Co. Ltd.'s CEO has espoused R&D and promotional strategy shifts for the company, unveiling a 2011-2013 mid-range plan to overcome current and upcoming patent losses of its major products. The company expects to rebound to 2010 levels by 2015 on the back of more efficient marketing and R&D, but implementation of a corporate shift will be vital to its success
You may also be interested in...
As Takeda Integrates Its Nycomed Acquisition, Europe Bears Brunt Of Job Cuts
Takeda is to close two R&D facilities in Germany and to cut commercial activities in the U.S., as it looks for cost savings from the 2011 acquisition of Nycomed.
PharmAsia News Favorite Stories From 2011
If you missed some of the highlights of 2011, here’s your opportunity to check out some of our favorite stories from the year, as chosen by the editors of PharmAsia News.
AstraZeneca Invests $200 Million For Manufacturing Plant In China Medical City
AstraZeneca PLC has announced a plan to invest $200 million to build a new manufacturing plant inside Taizhou, Jiangsu-based China Medical City